Stringent regulations by the regulatory agencies is expected to hinder market growth. In September 2015, the European Commission adopted the regulation establishing maximum residue limits for virginiamycin in poultry species, which is valid throughout the European Union.
In Denmark over 105 metric tonnes of antibiotics were used as growth promotion, after few years its usage failed which further accompanied by diminution of resistance to virginiamycin. Virginiamycin was banned in Denmark in 1999. The early ban on growth promoters in Denmark caused a drastic increase in use of therapeutic antibiotics in response to diseases such as colibacillosis and ileitis. Moreover, signs of allergic reaction to virginiamycin such as maculopapular eruption, anaphylactic reactions, eczema appearance on initial areas of contact dermatitis, and lesions are also expected to restrain the virginiamycin market growth.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients